Gates Foundation and UK Government join CARB-X
The Bill & Melinda Gates Foundation and the UK Government’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) have joined the CARB-X partnership, which supports global scientific research to develop new vaccines, preventatives and other products against drug-resistant bacterial infections, particularly among vulnerable populations in low- and middle-income countries.
EU calls for global ban on cosmetics animal testing
Ministers of the European Parliament have called for an end to cosmetics animal testing and urged the EU to launch a ‘diplomatic drive’ for a worldwide ban before 2023.
DuPont and ADM open world-first FDME pilot production facility
DuPont Industrial Biosciences and Archer Daniels Midland Company (ADM) have opened the world’s first biobased furan dicarboxylic methyl ester (FDME) pilot production facility in Decatur, Illinois, US.
FDME is a molecule derived from fructose that can be used to create a variety of biobased chemicals and materials, including plastics, that can be more cost-effective, efficient and sustainable than their fossil fuel- based counterparts.
EU votes to ban neonicotinoids
EU member states have voted to impose a near- total ban on neonicotinoid insecticides – the most widely used class of insecticides in the world – across the region. The ban will cover all crops grown outdoors, but growers will still be free to use them in greenhouses across the EU.
Takeda and Shire settle on US$62 billion deal
After months of discussions, Japan’s Takeda Pharmaceutical Company has reached an agreement to acquire Shire for US$62 billion (see SCM, May, p.20). The acquisition is expected to create a global, R&D-driven biopharmaceutical leader headquartered in Japan and better position Takeda to deliver highly-innovative medicines and transformative care globally. The transaction is expected to close in the first half of 2019.
CPhI: Science fiction and innovation
This year’s InformEx/CPhI North America event was buzzing, with thousands of attendees and over 25 high-profile speakers in a conference programme focused on the latest drug development innovations and manufacturing technologies.
The future of medicines and advances made so far were hot topics at this year’s event, held in Philadelphia on the 24-26 April.